PMID- 36211670
OWN - NLM
STAT- MEDLINE
DCOM- 20221011
LR  - 20230124
IS  - 2296-2565 (Electronic)
IS  - 2296-2565 (Linking)
VI  - 10
DP  - 2022
TI  - Cost-effectiveness of various immunization schedules with inactivated Sabin 
      strain polio vaccine in Hangzhou, China.
PG  - 990042
LID - 10.3389/fpubh.2022.990042 [doi]
LID - 990042
AB  - BACKGROUND: It is necessary to select suitable inactivated poliovirus 
      vaccine(IPV) and live, attenuated oral poliovirus vaccine (OPV) sequential 
      immunization programs and configure the corresponding health resources. An 
      economic evaluation was conducted on the sequential procedures of Sabin 
      strain-based IPV (sIPV) and bivalent OPV (bOPV) with different doses to verify 
      whether a cost-effectiveness target can be achieved. This study aimed to evaluate 
      the cost-effectiveness of different sIPV immunization schedules, which would 
      provide convincing evidence to further change the poliovirus vaccine (PV) 
      immunization strategies in China. METHODS: Five strategies were included in this 
      analysis. Based on Strategy 0(S(0)), the incremental cost (IC), incremental 
      effect (IE), and incremental cost-effectiveness ratio (ICER) of the four 
      different strategies (S(1)/S(2)/S(3)/S(4)) were calculated based on the 
      perspective of the society. Seven cost items were included in this study. Results 
      of field investigations and expert consultations were used to calculate these 
      costs. RESULTS: The ICs of S(1)/S(2)/S(3)/S(4) was Chinese Yuan (CNY) 30.77, 
      68.58, 103.82, and 219.82 million, respectively. The IE of vaccine-associated 
      paralytic poliomyelitis (IE(VAPP)) cases of S(1)/S(2)/S(3)/S(4) were 0.22, 0.22, 
      0.22, and 0.11, respectively, while the IE of disability-adjusted life-years 
      (IE(DALY)) of S(1)/S(2)/S(3)/S(4) were 8.98, 8.98, 8.98, and 4.49, respectively. 
      The ICER(VAPP) of S(1)/S(2)/S(3)/S(4) gradually increased to CNY 13.99, 31.17, 
      47.19, and 199.83 million/VAPP, respectively. The ICER(DALY) of 
      S(1)/S(2)/S(3)/S(4) also gradually increased to CNY 0.34, 0.76, 1.16, and 4.90 
      million/DALY, respectively. CONCLUSION: ICER(VAPP) and ICER(DALY) were 
      substantially higher for S(3) (four-sIPV) and S(4) (replacement of self-funded 
      sIPV based on one-sIPV-three-bOPV). Two-sIPV-two-bOPV had a cost-effectiveness 
      advantage, whereas S2/S3/S4 had no cost-effectiveness advantage.
CI  - Copyright (c) 2022 Xu, Liu, Wang, Che, Du, Zhang, Gu, Zhang and Jiang.
FAU - Xu, Yuyang
AU  - Xu Y
AD  - Department of Expanded Program on Immunization, Hangzhou Center for Disease 
      Control and Prevention, Hangzhou, China.
FAU - Liu, Yan
AU  - Liu Y
AD  - Department of Expanded Program on Immunization, Hangzhou Center for Disease 
      Control and Prevention, Hangzhou, China.
FAU - Wang, Jun
AU  - Wang J
AD  - Department of Expanded Program on Immunization, Hangzhou Center for Disease 
      Control and Prevention, Hangzhou, China.
FAU - Che, Xinren
AU  - Che X
AD  - Department of Expanded Program on Immunization, Hangzhou Center for Disease 
      Control and Prevention, Hangzhou, China.
FAU - Du, Jian
AU  - Du J
AD  - Department of Expanded Program on Immunization, Hangzhou Center for Disease 
      Control and Prevention, Hangzhou, China.
FAU - Zhang, Xiaoping
AU  - Zhang X
AD  - Department of Expanded Program on Immunization, Hangzhou Center for Disease 
      Control and Prevention, Hangzhou, China.
FAU - Gu, Wenwen
AU  - Gu W
AD  - Department of Expanded Program on Immunization, Hangzhou Center for Disease 
      Control and Prevention, Hangzhou, China.
FAU - Zhang, Xuechao
AU  - Zhang X
AD  - Department of Expanded Program on Immunization, Hangzhou Center for Disease 
      Control and Prevention, Hangzhou, China.
FAU - Jiang, Wei
AU  - Jiang W
AD  - Department of Expanded Program on Immunization, Hangzhou Center for Disease 
      Control and Prevention, Hangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220923
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
RN  - 0 (Poliovirus Vaccine, Inactivated)
RN  - 0 (Poliovirus Vaccine, Oral)
SB  - IM
MH  - Cost-Benefit Analysis
MH  - Humans
MH  - Immunization Schedule
MH  - *Poliomyelitis/prevention & control
MH  - *Poliovirus
MH  - Poliovirus Vaccine, Inactivated
MH  - Poliovirus Vaccine, Oral
PMC - PMC9545176
OTO - NOTNLM
OT  - IPV
OT  - Sabin strain
OT  - cost-effectiveness
OT  - dose
OT  - immunization schedules
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/10/11 06:00
MHDA- 2022/10/12 06:00
PMCR- 2022/09/23
CRDT- 2022/10/10 03:59
PHST- 2022/07/09 00:00 [received]
PHST- 2022/08/24 00:00 [accepted]
PHST- 2022/10/10 03:59 [entrez]
PHST- 2022/10/11 06:00 [pubmed]
PHST- 2022/10/12 06:00 [medline]
PHST- 2022/09/23 00:00 [pmc-release]
AID - 10.3389/fpubh.2022.990042 [doi]
PST - epublish
SO  - Front Public Health. 2022 Sep 23;10:990042. doi: 10.3389/fpubh.2022.990042. 
      eCollection 2022.